189 related articles for article (PubMed ID: 36875301)
1. Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation.
Okauchi S; Miyazaki K; Shiozawa T; Yamada H; Satoh H; Hizawa N
Cancer Diagn Progn; 2023; 3(2):244-250. PubMed ID: 36875301
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
Hattori S; Okauchi S; Sasatani Y; Ohara G; Miyazaki K; Sato S; Kodama T; Shiozawa T; Satoh H; Hizawa N
Anticancer Res; 2022 Sep; 42(9):4589-4595. PubMed ID: 36039463
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
Front Oncol; 2021; 11():704475. PubMed ID: 34631533
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
[TBL] [Abstract][Full Text] [Related]
6. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
[TBL] [Abstract][Full Text] [Related]
7. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
[No Abstract] [Full Text] [Related]
10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
11. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
12. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
14. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
[TBL] [Abstract][Full Text] [Related]
15. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Huang DD; Liao BC; Hsu WH; Yang CY; Lin YT; Wu SG; Tsai TH; Chen KY; Ho CC; Liao WY; Shih JY; Yu CJ; Yang JC; Cheng AL; Shen YC
Oncology; 2024; 102(4):318-326. PubMed ID: 37778345
[TBL] [Abstract][Full Text] [Related]
16. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
Front Oncol; 2021; 11():739090. PubMed ID: 34888234
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]